Among the genetic factors, FLT3-ITD, an internal tandem duplications (ITD) in fms-like tyrosine kinase 3 (FLT3), is observed in approximately 20–30% of AML patients and is associated with aggressive disease progression, worse prognosis, high risk of relapse, and shorter overall survival [3]. Here, FLT3 is linked to acute myeloid leukemia.